Astellas buys Xyphos Biosciences in $665 million dealChristian Fernsby ▼ | December 27, 2019
Astellas Pharma and Xyphos Biosciences announced that Astellas has acquired Xyphos.
Acquisition Xyphos Biosciences
Topics: Astellas Xyphos Biosciences
Considering the acquisition, $120 million was paid upon closing of the acquisition, and Xyphos became a wholly owned subsidiary of Astellas.
In addition to this payment and potential future development milestone payments, it will provide a total transaction value of $665 million. ■